T-cell receptor on cytokine-induced killer cell (TCR (on CIK cell))

The T-cell receptor on cytokine-induced killer cells (TCR on CIK cells) is a membrane-bound heterodimeric protein complex responsible for antigen-specific recognition, consisting typically of alpha (α) and beta (β) chains associated with the CD3 signal transduction subunits[1][5][7][9][8]. In CIK cells—a mixed population with both T-cell and natural killer (NK) features—the TCR mediates classical MHC-restricted immune recognition and cytotoxicity, while concurrent expression of activating NK receptors (such as NKG2D, DNAM-1, NKp30) allows for non-MHC-restricted killing of either tumor or virus-infected cells[8]. Engagement of the TCR with peptide-MHC triggers phosphorylation of CD3 ITAM motifs, which initiates downstream signaling cascades leading to cell activation, cytotoxic granule release, and cytokine production[1][7][9][8]. The receptor’s molecular specificity is generated through V(D)J recombination, yielding tremendous antigen diversity[1][5]. In clinical practice, CIK cells containing functional TCRs are used in adoptive cell therapy to treat cancers and control infections after transplantation due to their dual-mode effector function—targeting both specific antigens and MHC-independent stress ligands[8][4]. Note: - The name "T-cell receptor on CIK cells" is valid: it describes the TCR expressed in the context of CIK cells, which retain antigen-specific cytotoxicity via the TCR and acquire additional NK-like functions through other receptors[8]. - There is no evidence the entry is misspelled or technically incorrect; TCR is universally present in T cells and, by extension, in CIK cells which are derived from T lymphocytes[8][4].

Other names

TCRT-cell receptorTCR complexTCR/CD3 complexT-cell antigen receptor

Activation: Engagement with cognate peptide-MHC complexes triggers TCR activation, leading to CD3-associated ITAM phosphorylation, intracellular signaling, and cytotoxicity[1][7][9]. Inhibition: Kinase inhibitors block downstream TCR signaling and T-cell activation[9]. Immune modulation: Immune checkpoint blockade restores/enhances TCR-mediated activation.